FOSUN HEALTH Logo

Cervical Cancer Overview

catalogue

Cervical Cancer Overview

Cervical Cancer Overview

The cervix is the lower part of the uterus, and almost every cervical cancer begins after an HPV infection that the body failed to clear. Because the infection is preventable and the precancer is visible, this is among the most preventable of cancers — and when it does develop, the stage decides whether treatment is a cone biopsy, an operation, or radiotherapy with chemotherapy.

Cervical Cancer Overview
  • of cervical cancers are linked to a persistent HPV infection (WHO)

  • two viral types account for roughly 70% of cases — and are covered by every vaccine

  • the staging system for this cancer now explicitly includes imaging findings

  • from complete records to a personalized MDT plan

What cervical cancer is

The cervix is the narrow lower part of the uterus that opens into the vagina, and its surface carries two kinds of lining: squamous cells on the outer portion facing the vagina, and glandular cells lining the canal that leads up into the uterus. The junction between the two — the transformation zone — is where almost all cervical cancers begin, and it is precisely the area a screening test samples.

The disease develops slowly in most cases. A high-risk HPV infection, acquired through sexual contact, is cleared by the immune system within a year or two in the great majority of people. When it persists instead, the viral genes disturb the way the lining cells mature, first producing cervical intraepithelial neoplasia (CIN) — a precancer confined to the surface — and, over years, an invasive cancer that has grown through the basement membrane into the underlying tissue. That long interval between infection, precancer and cancer is the reason screening works here better than for almost any other cancer.

It also spreads in a predictable pattern, which matters for treatment: first into the tissue beside the cervix (the parametrium) and the upper vagina, then to the lymph nodes of the pelvis and later those along the aorta, and only in advanced disease to distant organs. Surgery removes the cervix and the parametrium together for early disease, while radiotherapy plus chemotherapy covers the same territory without an operation for locally advanced disease — which is why stage, more than anything else, decides the plan.

The main types

Cervical cancer is classified by the cell it arises from, and the type influences both how it is detected and how it behaves:

  • Squamous cell carcinoma — arises from the flat cells on the outer surface, is the commonest type worldwide, and is strongly linked to HPV 16. It is the type most readily caught by conventional cytology.
  • Adenocarcinoma — arises from the glandular cells of the cervical canal. Its share has been rising everywhere, it sits higher in the canal where a smear samples less reliably, and HPV testing catches it better than cytology does.
  • Adenosquamous and rare types — tumours with both components, and uncommon varieties such as neuroendocrine or small cell carcinoma. Each is treated on its own protocol rather than as an ordinary cervical cancer.
  • Precancer (CIN / AIS) — cervical intraepithelial neoplasia on the surface and adenocarcinoma in situ in the canal are not cancer, but treating them is what prevents cancer from ever developing.

The type is reported on every pathology specimen, and it carries practical consequences: adenocarcinoma argues for HPV-based screening and careful assessment of the canal, rare types can change the chemotherapy used, and both influence how follow-up is arranged after treatment.

What each stage means

Staging uses the FIGO 2018 system, which — unlike its predecessors — explicitly incorporates MRI and PET-CT findings, and even pathology from removed nodes. The stages relevant to treatment decisions are:

Stage In plain terms How it is usually approached
IA1 Microscopic invasion no deeper than 3 mm, found on a cone or a biopsy Cone biopsy alone in most cases; no hysterectomy required
IB1 Tumour 2 cm or smaller, confined to the cervix Radical hysterectomy — or radical trachelectomy where fertility matters
IB2–IB3 Tumour between 2 and 4 cm, or larger than 4 cm, still confined to the cervix Surgery for IB2; chemoradiotherapy and brachytherapy for IB3
IIB Tumour has grown into the parametrium, the tissue beside the cervix Definitive chemoradiotherapy with brachytherapy
IIIC Pelvic nodes involved (IIIC1) or para-aortic nodes involved (IIIC2) Chemoradiotherapy with an extended field; surgical staging may precede it
IVA / IVB Invasion of bladder or rectal lining, or distant spread to lung, liver, bone Systemic treatment, with radiotherapy for bleeding or symptom control

Two boundaries inside this table carry most of the decisions. The first is tumour size at 2 and 4 centimetres: up to 2 cm, fertility-sparing surgery is an option; beyond 4 cm, most guidelines move to chemoradiotherapy instead of surgery. The second is the parametrium: once tumour reaches it, an operation is generally replaced by radiotherapy with concurrent chemotherapy, because the radiotherapy field covers the same tissue more completely than surgery can.

Because FIGO 2018 counts involved nodes as stage IIIC even when the tumour itself is small, the imaging report directly changes the treatment category — which is why MRI and PET-CT are done before the plan is set, not after.

The markers that guide treatment

Cervical cancer is driven by viral oncogenes rather than by a wide range of targetable mutations, but a short list of markers determines eligibility for immunotherapy and is tested on the biopsy:

Marker What it is How it changes management
PD-L1 An immune checkpoint protein reported as a combined positive score (CPS) from the biopsy A CPS of 1 or more supports adding pembrolizumab to chemotherapy, with or without bevacizumab, in advanced disease
Mismatch repair / MSI status A rare pattern in which DNA repair errors accumulate Makes a PD-1 inhibitor likely to work regardless of PD-L1, and is worth requesting whenever immunotherapy is considered
Tumour mutational burden (TMB-H) An unusually high number of mutations per megabase An alternative route to pembrolizumab where PD-L1 is negative but the tumour is mutation-rich
NTRK fusions Very uncommon gene fusions reported in occasional cases Qualify for TRK-inhibitor treatment when no standard option remains

The practical point: request PD-L1 and mismatch repair testing at the time of diagnosis rather than when advanced disease appears, because the original biopsy is usually the best tissue available and a later re-biopsy can be difficult to arrange.

Why patients come to China for cervical cancer care

Cervical cancer care rewards exactly the things a high-volume national network provides — brachytherapy quality, surgical volume, and screening infrastructure that recognises precancer on sight.

  • Brachytherapy as a core skill — internal radiotherapy delivered into the cervix is what makes chemoradiotherapy complete for locally advanced disease, and centres that perform it routinely plan it with MRI guidance.
  • Nerve-sparing radical surgery — radical hysterectomy that removes the parametrium while preserving bladder, bowel and, in selected cases, sexual function, done by open or minimally invasive approach.
  • Fertility-sparing operations — radical trachelectomy and large-cone procedures for tumours of 2 cm or less, performed by teams who also manage the pregnancies that follow.
  • Immunotherapy access — PD-1 inhibitors combined with chemotherapy and bevacizumab for advanced disease, with the molecular testing arranged in-house.
  • Screening and colposcopy depth — China runs large-scale cervical screening, so the ability to read colposcopy accurately and to treat CIN before it becomes cancer is routine practice.
  • Coordinated follow-up — international patients keep imaging and examination schedules across time zones through the network's international service.

Two practical consequences follow. The choice between an operation and chemoradiotherapy depends on stage as assessed by MRI — so the imaging, not just the biopsy, should be sent. And because brachytherapy is what completes treatment for locally advanced disease, it matters that the treating centre performs it routinely. Send complete records and the written assessment is returned within 48 hours of the file being complete.

Frequently Asked Questions

Is cervical cancer curable?

It is, particularly when found early — and this cancer offers two routes that few others do. Precancer (CIN) is treated before it ever becomes cancer, and microscopic stage IA disease is usually treated by cone biopsy alone, with no hysterectomy. For tumours confined to the cervix, radical surgery is curative for a large proportion of patients, and locally advanced disease is treated with curative intent using chemoradiotherapy and brachytherapy. The honest framework is that curability depends on stage, which is why MRI and nodal imaging are done before treatment is chosen.

Is HPV infection the same as cervical cancer?

No, and the difference matters. HPV is an extremely common infection that most people acquire and clear without ever knowing they had it. Only infections that persist for years — a minority — can drive the cells of the cervix toward precancer and then cancer, a process that usually takes many years. An HPV-positive screening result is a prompt for closer follow-up, not a diagnosis of cancer.

Can I still have children after treatment?

Often, yes, and it depends on how early the tumour is. Microscopic disease is treated by cone biopsy, which leaves the uterus intact. For tumours of 2 cm or less, radical trachelectomy removes the cervix and the tissue beside it while keeping the body of the uterus, and pregnancies after trachelectomy are well described. Beyond those boundaries, hysterectomy or chemoradiotherapy ends fertility, which is why the staging MRI should be completed before any decision is made.

Why does treatment sometimes skip surgery altogether?

Because for locally advanced disease radiotherapy does the job surgery cannot. Once tumour has reached the parametrium or the pelvic nodes, removing it completely would require removing tissue that carries bladder and bowel function, and the operation would be incomplete. Concurrent chemoradiotherapy, completed by brachytherapy, treats the same territory — including the nodes — without that sacrifice, which is why stage IIB and above is treated without an operation.

Send your MRI and staging reports, get a written plan

Upload the colposcopy and biopsy reports, the staging MRI, any CT or PET-CT, and the pathology from any procedure already performed. Our gynaecological oncology team will return a written assessment within 48 hours of the file being complete — including whether cone biopsy, radical surgery or chemoradiotherapy is the appropriate route.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*